Oppenheimer Maintains Outperform on Q32 Bio, Raises Price Target to $40
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Jay Olson maintains Q32 Bio (NASDAQ:QTTB) with a Outperform and raises the price target from $20 to $40.
Oppenheimer analyst Jay Olson maintains Q32 Bio (NASDAQ:QTTB) with a Outperform and raises the price target from $20 to $40.